Based on a decade of prostate cancer studies by prominent researchers and clinical professionals at the University of Iowa Hospitals and Clinics, Ohana has developed the novel Pro-V vaccine, an immuno-therapeutic vaccine that employs the novel prime-boost methodology to destroy targeted tumor cells.  Ohana’s Pro-V destroys antigen-expressing tumor cells and has no effect on normal cells. Additionally Pro-V may have the remarkable potential for cancer prevention for patients who are at high risk for developing prostate cancer.. Customer segments comprise of recurrent prostate cancer patients, urologists, oncologists.

Venture Information
Stage: 
Pre-Clinical
Industry: 
Therapeutics & Drugs
Technology or Science Area: 
Cancer vaccine to cure recurring prostate cancer
Type of Product: 
Medical Vaccine
Company Information
Founders: 
David Lubaroff